High UHRF1 levels, coupled with low TSG expression, are negatively associated with CRC progression and reduced patient survival, suggesting the need to explore critical UHRF1 domains and their relevance to CRC prognosis, pointing toward novel therapeutic avenues [106]. This evidence concerns the gene UHRF1 and colorectal carcinoma.